Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Conditions
Interventions
BMS-986340
BMS-936558-01
+1 more
Locations
48
United States
Community Cancer Institute
Clovis, California, United States
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
University of Iowa
Iowa City, Iowa, United States
John Theurer Cancer Center
Hackensack, New Jersey, United States
Local Institution - 0006
New York, New York, United States
Start Date
May 27, 2021
Primary Completion Date
July 7, 2028
Completion Date
July 7, 2028
Last Updated
April 13, 2026
NCT04977453
NCT06349642
NCT05639972
NCT07225530
NCT07209917
NCT05581004
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
855-907-3286Clinical.Trials@bms.comFirst line of the email MUST contain NCT # and Site #.
CONTACT
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions